

Burjeel Holdings PLC

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE MONTHS PERIOD ENDED 31 MARCH 2025 (UNAUDITED)



**ERNST & YOUNG – MIDDLE EAST
(ADGM BRANCH)**
P.O. Box 136
Tamouh Tower, 16th Floor, Office No. 1603
Tamouh, Al Reem Island
Emirate of Abu Dhabi
United Arab Emirates

Tel: +971 2 417 4400
+971 2 627 7522
Fax: +971 2 627 3383
abudhabi@ae.ey.com
www.ey.com

ADGM Registered No. 000001136

REPORT ON REVIEW OF INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TO THE SHAREHOLDERS OF

BURJEEL HOLDINGS PLC

Introduction

We have reviewed the accompanying interim condensed consolidated financial statements of Burjeel Holdings PLC (the “Company”) and its subsidiaries (together referred to as the “Group”) as at 31 March 2025, comprising of the interim condensed consolidated statement of financial position as at 31 March 2025, and the related interim condensed consolidated statements of comprehensive income, changes in equity and cash flows for the three months period then ended and explanatory notes. Management is responsible for the preparation and fair presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard 34 *Interim Financial Reporting* (“IAS 34”). Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects in accordance with IAS 34.

For Ernst & Young Middle East (ADGM Branch)

Walid J Nakfour

6 May 2025
Abu Dhabi, United Arab Emirates

Burjeel Holdings PLC

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the three months period ended 31 March 2025 (unaudited)

	Notes	<i>Three months period ended 31 March</i>	
		<i>2025</i> <i>AED</i>	<i>2024</i> <i>AED</i>
Revenue	4	<u>1,274,063,109</u>	<u>1,204,982,594</u>
Doctors' and other employees' salaries and emoluments		(586,229,181)	(527,831,205)
Inventories consumed		(316,388,154)	(301,533,209)
Depreciation on property and equipment	6	(59,218,540)	(55,479,377)
Amortisation of intangible assets		(1,219,221)	(1,348,693)
Depreciation on right-of-use assets		(34,953,834)	(29,467,359)
Provision for expected credit losses	10	(38,857,506)	(22,100,282)
Other expenses	5	<u>(156,470,295)</u>	<u>(111,145,270)</u>
OPERATING PROFIT FOR THE PERIOD		80,726,378	156,077,199
Finance costs		(40,911,578)	(32,874,044)
Change in fair value of financial assets carried at fair value through profit and loss		-	(11,796,536)
Share of profit from associates		<u>4,747,982</u>	<u>3,895,078</u>
PROFIT FOR THE PERIOD BEFORE TAX		44,562,782	115,301,697
Income tax	15	<u>(5,365,641)</u>	<u>(10,939,313)</u>
PROFIT FOR THE PERIOD		39,197,141	104,362,384
Other comprehensive income		-	-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		<u>39,197,141</u>	<u>104,362,384</u>
Profit for the period and total comprehensive income for the period attributable to:			
Equity holders of the Parent Company		36,379,277	102,018,831
Non-controlling interests		<u>2,817,864</u>	<u>2,343,553</u>
		<u>39,197,141</u>	<u>104,362,384</u>
Earnings per share attributable to equity holders of the Parent Company			
- basic and diluted earnings per share (AED)	16	<u>0.007</u>	<u>0.020</u>

The accompanying notes 1 to 17 form an integral part of these interim condensed consolidated financial statements.

Burjeel Holdings PLC

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION At 31 March 2025

		(Unaudited) 31 March 2025 AED	(Audited) 31 December 2024 AED
	Notes		
ASSETS			
Non-current assets			
Property and equipment	6	1,942,472,300	1,931,590,098
Intangible assets		15,156,379	16,029,401
Right-of-use assets		1,272,359,899	1,278,257,468
Capital work in progress		101,654,020	50,327,725
Goodwill	12	80,510,986	-
Investment in associates		35,317,161	30,569,179
Deferred tax asset		266,046	-
Term deposits		<u>2,552,500</u>	<u>2,552,500</u>
		<u>3,450,289,291</u>	<u>3,309,326,371</u>
Current assets			
Inventories		281,545,859	277,222,606
Accounts receivable and prepayments	10	2,196,309,716	2,032,497,509
Amounts due from related parties	8	21,190,207	21,493,157
Bank balances and cash	7	<u>269,577,822</u>	<u>238,196,268</u>
		<u>2,768,623,604</u>	<u>2,569,409,540</u>
TOTAL ASSETS		<u>6,218,912,895</u>	<u>5,878,735,911</u>
EQUITY AND LIABILITIES			
Equity			
Share capital		520,513,417	520,513,417
Share premium		366,854,049	366,854,049
Other reserve		3,039,504	3,039,504
Shareholder's contribution		3,556,305	3,556,305
Retained earnings		<u>934,398,146</u>	<u>898,018,869</u>
Equity attributable to equity holders of the parent		1,828,361,421	1,791,982,144
Non-controlling interests		<u>61,496,721</u>	<u>50,338,738</u>
Total equity		<u>1,889,858,142</u>	<u>1,842,320,882</u>
Non-current liabilities			
Interest bearing loans and borrowings	9	1,008,721,182	877,081,001
Lease liabilities		1,338,172,169	1,344,437,110
Employees' end of service benefits		<u>177,670,269</u>	<u>168,181,211</u>
		<u>2,524,563,620</u>	<u>2,389,699,322</u>
Current liabilities			
Accounts payable and accruals		1,230,667,696	1,100,801,238
Lease liabilities		118,119,049	111,078,336
Interest bearing loans and borrowings	9	331,894,401	331,367,148
Income tax payable	15	43,696,335	38,064,648
Amounts due to related parties	8	<u>80,113,652</u>	<u>65,404,337</u>
		<u>1,804,491,133</u>	<u>1,646,715,707</u>
Total liabilities		<u>4,329,054,753</u>	<u>4,036,415,029</u>
TOTAL EQUITY AND LIABILITIES		<u>6,218,912,895</u>	<u>5,878,735,911</u>

Mr. John Sunil
Chief Executive Officer

Mr. Safer Ahmed Ullatt
Co-Chief Executive Officer

Mr. Muhammed Shihabuddin
Chief Financial Officer

The accompanying notes 1 to 17 form an integral part of these interim condensed consolidated financial statements.

Burjeel Holdings PLC

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the three months period ended 31 March 2025 (unaudited)

	Attributable to the equity holders of Parent							
	Share capital AED	Share premium AED	Other reserve AED	Shareholder's contribution AED	Retained earnings AED	Total AED	Non-controlling interest AED	Total equity AED
As at 1 January 2024 (audited)	520,513,417	366,854,049	3,039,504	3,553,665	615,624,704	1,509,585,339	47,471,593	1,557,056,932
Profit for the period (unaudited)	-	-	-	-	102,018,831	102,018,831	2,343,553	104,362,384
Total comprehensive income for the period (unaudited)	-	-	-	-	102,018,831	102,018,831	2,343,553	104,362,384
Balance at 31 March 2024 (unaudited)	520,513,417	366,854,049	3,039,504	3,553,665	717,643,535	1,611,604,170	49,815,146	1,661,419,316
As at 1 January 2025 (audited)	520,513,417	366,854,049	3,039,504	3,556,305	898,018,869	1,791,982,144	50,338,738	1,842,320,882
Profit for the period (unaudited)	-	-	-	-	36,379,277	36,379,277	2,817,864	39,197,141
Total comprehensive income for the period (unaudited)	-	-	-	-	36,379,277	36,379,277	2,817,864	39,197,141
Share capital introduced (unaudited)	-	-	-	-	-	-	365,937	365,937
Additional contribution (unaudited)	-	-	-	-	-	-	6,038,937	6,038,937
Acquisition of a subsidiary (unaudited)	-	-	-	-	-	-	1,935,245	1,935,245
Balance at 31 March 2025 (unaudited)	520,513,417	366,854,049	3,039,504	3,556,305	934,398,146	1,828,361,421	61,496,721	1,889,858,142

The accompanying notes 1 to 17 form an integral part of these interim condensed consolidated financial statements.

Burjeel Holdings PLC

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the three months period ended 31 March 2025 (unaudited)

		<i>Three months period ended 31 March</i>	
		<i>2025</i>	<i>2024</i>
		<i>Unaudited</i>	<i>Unaudited</i>
	<i>Notes</i>	<i>AED</i>	<i>AED</i>
OPERATING ACTIVITIES			
Profit before tax		44,562,782	115,301,697
Adjustments for:			
Depreciation on property and equipment	6	59,218,540	55,479,377
Amortisation of intangible assets		1,219,221	1,348,693
Depreciation on right-of-use assets		34,953,834	29,467,359
Provision for expected credit losses	10	38,857,506	22,100,282
Change in fair value of financial assets carried at fair value through profit and loss		-	11,796,536
Share of profit of investments in associates		(4,747,982)	(3,895,078)
Provision for employees' end of service benefits		12,620,314	11,163,013
Lease adjustment		38,505	(1,447,545)
Gain on disposal of property and equipment	6	-	(54,762)
Change in fair value of derivative financial instruments	5	-	(8,454,919)
Finance costs		<u>40,911,578</u>	<u>32,874,044</u>
		227,634,298	265,678,697
Working capital adjustments:			
Inventories		(2,772,924)	46,134
Accounts receivable and prepayments		(183,047,960)	(215,989,668)
Amounts due from related parties		332,362	3,408,483
Accounts payable and accruals		112,873,722	71,032,702
Amounts due to related parties		<u>14,611,866</u>	<u>16,339,979</u>
Cash generated from operations		169,631,364	140,516,327
Employees' end of service benefits paid		(5,063,589)	(5,626,408)
Finance costs paid		<u>(22,406,888)</u>	<u>(19,414,553)</u>
Net cash flows from operating activities		<u>142,160,887</u>	<u>115,475,366</u>
INVESTING ACTIVITIES			
Purchase of property and equipment	6	(43,394,665)	(37,276,365)
Additions to intangible assets		(346,199)	(379,301)
Additions to capital work in progress		(51,346,320)	(3,000,639)
Proceeds from disposal of property and equipment	6	-	54,762
Cash acquired against acquisition of subsidiaries	12	2,847,706	-
Cash paid against acquisition of subsidiaries	12	(106,410,568)	-
Proceeds from sale of financial assets carried at fair value through profit and loss		-	192,450
Dividend income received from associates, net of investment		-	<u>8,800,000</u>
Net cash flows used in investing activities		<u>(198,650,046)</u>	<u>(31,609,093)</u>
FINANCING ACTIVITIES			
Payment of principal portion of lease liabilities		(48,507,166)	(39,989,729)
Share capital introduced		365,937	-
Additional contribution by non-controlling interest		6,038,937	-
Repayment of interest bearing loans and borrowings	9	(20,026,995)	(182,013,277)
Proceeds from interest bearing loans and borrowings	9	<u>150,000,000</u>	<u>193,919,096</u>
Net cash flows from (used in) financing activities		<u>87,870,713</u>	<u>(28,083,910)</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS		31,381,554	55,782,363
Cash and cash equivalents at 1 January		<u>234,368,540</u>	<u>166,177,248</u>
CASH AND CASH EQUIVALENTS AT 31 MARCH	7	<u>265,750,094</u>	<u>221,959,611</u>

The accompanying notes 1 to 17 form an integral part of these interim condensed consolidated financial statements.

1 ACTIVITIES

Burjeel Holdings PLC (the “Company” or the “Parent”) is registered in Abu Dhabi Global Market (ADGM) under license number 000003466 as a Public Company Limited by Shares. The Company was incorporated on 7 January 2020 (the “inception date”). The registered address of the Company is 402-DO2, 15th Floor, Al Sarab Tower, Abu Dhabi Global Market Square, Maryah Island, Abu Dhabi, United Arab Emirates. The Company and its subsidiaries are collectively referred to as the Group (the “Group”).

The principal activity of the Company is to act as a holding company (Proprietary Investment Company) for the entities within the Group. The principal activities of the subsidiaries are to provide multi-speciality hospitals, medical, surgical and dental services and sale of pharmaceutical goods and medical equipment.

The shareholding of the Company is as follows:

VPS Healthcare Holdings PVT. Ltd	70.0%
Quant Lase Lab LLC	14.4%
SYA Holdings PVT. Ltd.	5.0%
Publicly traded	10.6%

The interim condensed consolidated financial statements were approved by the Board of Directors and authorised for issue on 6 May 2025.

2 BASIS OF PREPARATION

2.1 Statement of compliance

The interim condensed consolidated financial statements for the three months ended 31 March 2025 have been prepared in accordance with IAS 34 Interim Financial Reporting. The Group has prepared the financial statements on the basis that it will continue to operate as a going concern.

The interim condensed consolidated financial statements do not include all information and disclosures required in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (“IFRS”) and should be read in conjunction with the Group’s annual consolidated financial statements as at 31 December 2024. In addition, results for the three months period ended 31 March 2025 are not necessarily indicative of the results for the year ending 31 December 2025.

These interim condensed consolidated financial statements have been prepared on the historical cost basis, except for derivative financial instruments and financial assets carried at fair value through profit and loss which are stated fair value.

During the period, the Group has reclassified certain comparative amounts to conform to the presentation as in the current period.

The interim condensed consolidated financial statements are presented in United Arab Emirates Dirhams (“AED”), which is the functional currency of the Company and the presentational currency of the Group.

2 BASIS OF PREPARATION continued

2.2 Basis of consolidation

The interim condensed consolidated financial statements comprise the financial statements of the Company and its subsidiaries. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee)
- Exposure, or rights, to variable returns from its involvement with the investee
- The ability to use its power over the investee to affect its returns

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee
- Rights arising from other contractual arrangements
- The Group's voting rights and potential voting rights

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the period are included in the interim condensed consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

Profit or loss and each component of Other Comprehensive Income (OCI) are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

If the Group loses control over a subsidiary, it:

- Derecognises the assets (including goodwill) and liabilities of the subsidiary;
- Derecognises the carrying amount of any non-controlling interest;
- Derecognises the cumulative translation differences, recorded in equity;
- Recognises the fair value of the consideration received;
- Recognises the fair value of any investment retained;
- Recognises any surplus or deficit in profit or loss; and
- Reclassifies the parent's share of components previously recognized in other comprehensive income to profit or loss or retained earnings, as appropriate.

The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under IFRS 9, when applicable, or the cost on initial recognition of an investment in an associate or a joint venture.

3 MATERIAL ACCOUNTING POLICY INFORMATION

3.1 New standards, interpretations and amendments adopted by the Group

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of new standards effective as of 1 January 2025. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

One amendment applies for the first time in 2025, related to "Amendments to IAS 21: Lack of exchangeability", but does not have an impact on the interim condensed consolidated financial statements of the Group.

International Tax Reform—Pillar Two Model Rules – Amendments to IAS 12

On 11 February 2025, the Ministry of Finance (MoF) of the United Arab Emirates (UAE) released Cabinet Decision No. 142 of 2024 on the Imposition of Top-Up Tax on Multinational Enterprises (Cabinet Decision), introducing a Domestic Minimum Top-Up Tax (DMTT) on multinational enterprises (MNEs). Effective from fiscal years starting on or after 1 January 2025, the DMTT Imposes a top-up tax on low-taxed UAE entities, ensuring a minimum effective tax rate (ETR) of 15% in the UAE.

The Group is headquartered in the UAE and is within the scope of the OECD BEPS Pillar Two Global Anti-Base Erosion Model Rules (GloBE Rules). The Group has operations in countries where Pillar Two legislation are in effect during 2025 (e.g., UAE, Kingdom of Saudi Arabia and Oman). Based on the impact assessment performed by the Group, it may be able to meet certain reliefs and may not be required to pay additional taxes for the year under these tax rules. However, the Executive Regulations detailing the requirements and conditions for such relief have not been enacted yet as of the date of the approval of the interim condensed consolidated financial statements. The anticipated reliefs include a transitional DMTT exclusion of early phase international activity, where UAE DMTT liability would be reduced to nil for the first 5 years provided:

- the Multinational Enterprises ("MNE") Group is not located in more than 6 jurisdictions;
- the relevant entities are not subject to a qualified Income Inclusion Rule of another jurisdiction; and
- the net book value of tangible assets across all jurisdictions other than the "reference jurisdiction" (being the jurisdiction with the highest value of tangible assets) does not exceed EUR 50 million.

On 23 May 2023, the International Accounting Standards Board (IASB) issued amendments to IAS 12 Income Taxes (Amendments). The Amendments address concerns related to accounting and reporting of the Pillar Two income taxes. These Amendments are applicable for annual periods beginning on or after 1 January 2023. The Amendments introduce a mandatory temporary exception from recognizing and disclosing deferred taxes related to Pillar Two when the legislation is enacted. The Group has applied this mandatory exception to recognizing and disclosing information about deferred tax assets and liabilities arising from Pillar Two income taxes.

3.2 Significant accounting estimates and judgements

The preparation of the interim condensed consolidated financial statements in conformity with the IFRS requires management to make judgment, estimates and assumptions that affect the application of accounting policies and reported amounts of financial assets and liabilities and the disclosure of contingent liabilities. These judgments, estimates and assumptions also affect the revenue, expenses and provisions as well as fair value changes. Actual results may differ from these estimates.

These judgments, estimates and assumptions may affect the reported amounts in subsequent financial years. Estimates and judgments are currently evaluated and are based on historical experience and other factors.

In preparing these interim condensed consolidated financial statements, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty are the same as those applied to the annual consolidated financial statements as at and for the year ended 31 December 2024.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

4 REVENUE

4.1 Types of revenue

	<i>Three months period ended</i>	
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>31 March</i>	<i>31 March</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
Clinic revenue	1,217,176,185	1,164,577,346
Pharmacy sales	15,157,536	15,723,229
Other operating income	40,907,933	23,694,875
Revenue from customers	1,273,241,654	1,203,995,450
Rental income	821,455	987,144
	<u>1,274,063,109</u>	<u>1,204,982,594</u>

4.2 Revenue from customers – timing of recognition

	<i>Three months period ended</i>	
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>31 March</i>	<i>31 March</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
Outpatient – services rendered at the point in time	773,712,109	752,319,572
In patient – services rendered over the time	443,464,076	412,257,774
Pharmacy – services rendered at the point in time	15,157,536	15,723,229
Other operating income – services rendered at the point in time	10,862,453	8,070,965
Other operating income – services rendered over the time	30,045,480	15,623,910
	<u>1,273,241,654</u>	<u>1,203,995,450</u>

4.3 Revenue from customers by geographical markets

	<i>Three months period ended</i>	
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>31 March</i>	<i>31 March</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
United Arab Emirates	1,217,962,277	1,155,264,549
Sultanate of Oman	51,639,180	47,762,784
Kingdom of Saudi Arabia	3,640,197	968,117
	<u>1,273,241,654</u>	<u>1,203,995,450</u>

4.4 Revenue from customers by asset type

	<i>Three months period ended</i>	
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>31 March</i>	<i>31 March</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
Hospitals	1,114,926,085	1,073,884,379
Medical centres	102,250,100	90,692,967
Pharmacies	15,157,536	15,723,229
Others	40,907,933	23,694,875
	<u>1,273,241,654</u>	<u>1,203,995,450</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

4 REVENUE continued

Performance obligations

The performance obligation is satisfied based on the nature of medical services or upon delivery of the medical goods or supplies in case of pharmacy items. Certain contracts for the sale of pharmacy items provide customers with a right of return. However, the sales returns are negligible as compared to the gross revenue for the sale of pharmacy items. Based on the analysis of the historical data and experience, sales return is estimated to be less than 0.05% of the total sales made during a financial period. Considering that the sales returns of the Group are not significant, the Group has not recorded a refund liability and a right of return asset for anticipated sales returns as of the reporting dates.

In the Middle East, the normal business process associated with transactions with insurers includes a number of claims disallowed which is not paid by the insurer. These rejected claims could be for various technical or medical reasons. These rejections constitute variable consideration under IFRS 15. Variable consideration is recognised as revenue to the extent that it is highly probable that a reversal of revenue will not occur. Under IFRS 15, these rejected claims are recognised as part of revenue (decreasing the revenue recognised).

Rental income

The rental income received from external parties during the period from the letting of excess or unused spaces in the hospitals and medical centres. Rental income is based on individual lease agreements with a committed lease term of 1 year or less. Therefore, these are categorised as short-term leases.

There are no unsatisfied performance obligations as of the reporting dates; therefore, there are no transaction prices that are required to be allocated over the remaining or unsatisfied performance obligations.

5 OTHER EXPENSES

	<i>Three months period ended</i>	
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>31 March</i>	<i>31 March</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
Advertisement and marketing expenses	29,802,257	18,745,305
Repair and maintenance costs	26,404,923	19,851,252
Housekeeping and hospitality expenses	22,242,814	20,833,025
Utility charges	13,002,663	11,441,910
Legal and professional expenses	12,446,500	9,285,476
Hospital management project related costs	7,130,010	119,148
Transportation expenses	5,414,230	5,305,721
Security charges	4,603,912	4,030,762
Directors' remuneration (note 8)	4,561,449	4,561,449
Rent expenses	4,050,743	3,573,380
Printing and stationery costs	2,358,094	1,797,529
Bank charges	1,328,654	2,398,188
Credit card commissions	1,223,949	1,028,681
License fee software	1,111,980	794,940
Call centre expenses	709,923	635,115
Change in fair value of profit rate swaps	-	(8,454,919)
Miscellaneous expenses	<u>20,078,194</u>	<u>15,198,308</u>
	<u>156,470,295</u>	<u>111,145,270</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

6 PROPERTY AND EQUIPMENT

The movement in property and equipment pertains to additions of AED 43,394,665 for three months period ended 31 March 2025 (three months period ended 31 March 2024: AED 37,276,365) which comprises of building and leasehold improvements of AED 8,185,107 (2024: AED 8,235,160), medical equipment of AED 19,596,473 (2024: AED 15,805,645), furniture and fixtures of AED 3,861,439 (2024: AED 5,752,918), computer and office equipment of AED 10,898,035 (2024: AED 5,656,491) and motor vehicles of AED 853,611 (2024: AED 1,826,151).

Further, during the three months period ended 31 March 2025, leasehold improvements of AED 5,316,939 (2024: AED nil), medical equipment of AED 20,159,148 (2024: AED nil), furniture and fixtures of AED 120,353 (2024: AED nil), computer and office equipment of AED 742,524 (2024: AED nil) and motor vehicles of AED 347,088 (2024: AED nil), are acquired under IFRS 3 business combinations, representing book value at the acquisition date.

Further, during the three months period ended 31 March 2025, leasehold improvements amounting to AED 20,025 were transferred from capital work in progress (three months period ended 31 March 2024: AED nil).

During the three months period ended 31 March 2025, there were no disposals (three months period ended 31 March 2024, motor vehicles having net book value of nil were disposed at AED 54,762 resulting in gain on disposal by the same amount).

The depreciation charge for the three months period ended amounted to AED 59,218,540 (three months period ended 31 March 2024: AED 55,479,377).

See note 13 for capital commitments.

7 BANK BALANCES AND CASH

	31 March 2025 AED (Unaudited)	31 December 2024 AED (Audited)
Cash in hand	5,194,939	3,862,112
<i>Bank balances:</i>		
Current accounts	260,368,397	230,319,670
Fixed deposits	186,758	186,758
Margin deposits	<u>3,827,728</u>	<u>3,827,728</u>
Bank balances and cash	<u>269,577,822</u>	<u>238,196,268</u>

For the purpose of the interim condensed consolidated statement of cash flows, cash and cash equivalents comprise the following at 31 March 2025 and 31 December 2024:

	31 March 2025 AED (Unaudited)	31 December 2024 AED (Audited)
Bank balances and cash	269,577,822	238,196,268
Less: margin deposits	<u>(3,827,728)</u>	<u>(3,827,728)</u>
Cash and cash equivalents	<u>265,750,094</u>	<u>234,368,540</u>

Margin deposits are cash guarantees paid to various banks. These deposits are not liquid and are not readily convertible to cash as they are subordinated to the respective facilities. Therefore, these deposits are excluded from cash and cash equivalents.

The expected credit loss on bank balances is estimated to be immaterial as the Group only deals with reputable banks with good ratings.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

8 RELATED PARTY TRANSACTIONS AND BALANCES

These represent transactions with related parties, i.e. shareholders and senior management of the Group, and entities controlled, jointly controlled or significantly influenced by such parties. Pricing policies and terms of all transactions are approved by the management of the Group.

Transactions with related parties included in the interim condensed consolidated statement of comprehensive income are as follows:

	<i>Three months period ended</i>	
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>31 March</i>	<i>31 March</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
Revenue	<u>694,465</u>	<u>692,853</u>
Purchases	<u>6,546,399</u>	<u>5,923,669</u>
Doctors' and other employees' salaries and emoluments	<u>54,921</u>	<u>567,026</u>
Directors' remuneration (note 5)	<u>4,561,449</u>	<u>4,561,449</u>
Hospitality expenses	<u>7,410,240</u>	<u>6,498,885</u>
Others	<u>2,356,984</u>	<u>2,985,241</u>

Compensation of key management personnel

The remuneration of the members of key management during the period was as follows:

	<i>Three months period ended</i>	
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>31 March</i>	<i>31 March</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
Salaries and other benefits	<u>1,317,500</u>	<u>1,317,500</u>
Bonus	<u>-</u>	<u>4,750,000</u>
	<u>1,317,500</u>	<u>6,067,500</u>
Number of key management personnel	<u>2</u>	<u>2</u>
	<i>31 March</i>	<i>31 December</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
	<i>(Unaudited)</i>	<i>(Audited)</i>
Amounts due from related parties		
<i>Entities under common control</i>		
VPS Healthcare LLC	<u>12,305,285</u>	<u>12,305,285</u>
Others	<u>8,884,922</u>	<u>9,187,872</u>
	<u>21,190,207</u>	<u>21,493,157</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

8 RELATED PARTY TRANSACTIONS AND BALANCES continued

Outstanding balances at the period/ year end arise in the normal course of business and due to receipt and payment transactions. The Group have not recorded any impairment on amounts due from related parties. This assessment is undertaken each reporting date through examining the financial position of the related party and the market in which the related party operates.

	<i>31 March 2025 AED (Unaudited)</i>	<i>31 December 2024 AED (Audited)</i>
Amounts due to related parties		
<i>Entities under common control</i>		
Others	<u>80,113,652</u>	<u>65,404,337</u>

9 INTEREST BEARING LOANS AND BORROWINGS

	<i>31 March 2025 AED (Unaudited)</i>	<i>31 December 2024 AED (Audited)</i>
Term loan	1,085,536,178	952,742,827
Short-term loan	250,000,000	250,000,000
Vehicle loans	<u>5,079,405</u>	<u>5,705,322</u>
	<u>1,340,615,583</u>	<u>1,208,448,149</u>

Current and non-current portion of interest-bearing loans and borrowings can be analysed as follows:

	<i>31 March 2025 AED (Unaudited)</i>	<i>31 December 2024 AED (Audited)</i>
Non-current	1,008,721,182	877,081,001
Current	<u>331,894,401</u>	<u>331,367,148</u>
	<u>1,340,615,583</u>	<u>1,208,448,149</u>

Movement in the interest bearing loans and borrowings during the period / year is as follows:

	<i>31 March 2025 AED (Unaudited)</i>	<i>31 December 2024 AED (Audited)</i>
At 1 January	1,208,448,149	1,163,997,906
Acquisition under IFRS 3 business combination (note 12)	2,194,429	-
Additions during the period / year	150,000,000	466,171,580
Repayments during the period / year	<u>(20,026,995)</u>	<u>(421,721,337)</u>
	<u>1,340,615,583</u>	<u>1,208,448,149</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

9 INTEREST BEARING LOANS AND BORROWINGS continued

Interest rates

Interest rates on these loans and borrowings are at EIBOR plus a fixed margin. The range is as follows:

Commercial loans	- 10% per annum reducing balance (relating to acquisition during the quarter) and EIBOR + 1.65 to 1.9% (2024: EIBOR + 1.65 to 3%)
Vehicle loans	- 3% to 10% (2024: 3% to 10%)

10 ACCOUNTS RECEIVABLE AND PREPAYMENTS

	31 March 2025 AED (Unaudited)	31 December 2024 AED (Audited)
Trade receivables	2,749,783,566	2,604,112,888
Less: provision for expected credit losses	<u>(927,280,612)</u>	<u>(886,296,582)</u>
	1,822,502,954	1,717,816,306
Unbilled receivables	133,576,458	117,702,668
Less: provision for expected credit losses	<u>(4,059,070)</u>	<u>(2,425,101)</u>
	129,517,388	115,277,567
Advances and other receivables	141,700,886	134,553,059
Prepayments	78,942,176	44,731,334
Deposits	<u>23,646,312</u>	<u>20,119,243</u>
	<u>2,196,309,716</u>	<u>2,032,497,509</u>

Trade receivables and unbilled receivables include amounts due from insurance companies for goods sold or services performed in the ordinary course of business. Trade receivables are generally due for settlement within 90 days and therefore are all classified as current. Trade receivables and unbilled receivables are recognised initially at the amount of consideration that is unconditional. The Group holds the trade receivables and unbilled receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method.

Movement in the provision for expected credit losses is as follows:

	31 March 2025 AED (Unaudited)	31 December 2024 AED (Audited)
At 1 January	888,721,683	786,671,761
Acquisitions under IFRS 3 business combination	3,760,493	-
Charge for the year	38,857,506	102,749,138
Write off during the year	<u>-</u>	<u>(699,216)</u>
At 31 December	<u>931,339,682</u>	<u>888,721,683</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

10 ACCOUNTS RECEIVABLE AND PREPAYMENTS continued

As at 31 December, the ageing analysis of unimpaired trade receivables is as follows:

	<i>*Not due nor impaired</i>				<i>*Past due but not impaired</i>			
	<i>Total</i>	<i>Less than 30 days</i>	<i>31-60 days</i>	<i>61-90 days</i>	<i>91-120 days</i>	<i>121-180 days</i>	<i>181-300 days</i>	<i>More than 300 days</i>
	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>	<i>AED</i>
31 March 2025 (Unaudited)	1,822,502,954	282,351,473	330,694,432	303,665,124	183,468,714	303,042,909	331,907,487	87,372,815
31 December 2024 (Audited)	1,717,816,306	335,797,558	303,857,338	289,799,295	187,120,381	238,704,702	320,829,364	41,707,668

Unimpaired receivables are expected, on the basis of past experience, to be fully recoverable. It is not the practice of the Group to obtain collateral over receivables and the receivables are, therefore, unsecured. Neither past due nor impaired are those receivables which are under review and approval process with the insurance companies. Credit risk is limited to the carrying values of financial assets in the interim condensed consolidated statement of financial position.

* “Not due nor impaired” and “Past due but not impaired” are presented net of provision for expected credit losses.

11 SEGMENTAL REPORTING

For management purposes, the Group is organised into business units or segments based on its products and services and has four reportable segments as follows:

- Hospitals;
- Medical center;
- Pharmacies; and
- Others

Hospital includes entities that provide inpatient, day-care services and outpatient services to patients to diagnosis the disease and offer medical and surgical treatment as part of in-patient services.

Medical Centre includes entities which offer only outpatient services to patients which includes medical consultation, lab and radiology diagnostic treatment (if required), will refer the patient to hospitals for inpatient and day care services, if needed.

Pharmacies includes all the retail pharmacies which are outside the premises of the hospitals and medical centres. Pharmacies act as retail stores and selling pharmaceutical and cosmetic products.

Other represents business units that support the hospitals, medical center, and pharmacies to manage the supply chain, valet parking and claim submission etc.

No operating segments have been aggregated to form the above reportable operating segments.

The Chief Executive Officer of the Group is the Chief Operating Decision Maker (CODM) and monitors the operating results of the operating segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the interim condensed consolidated financial statements.

Segment performance is evaluated based on profit or loss including EBIT and EBITDA and is measured consistently with profit or loss in the interim condensed consolidated financial statements.

Burjeel Holdings PLC

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 31 March 2025 (Unaudited)

11 SEGMENTAL REPORTING continued

	Hospitals AED	Medical centre AED	Pharmacies AED	Others AED	Total segments AED	Adjustments and eliminations AED	Consolidation AED
31 March 2025							
Revenue							
Out patient revenue	706,732,500	103,540,797	-	-	810,273,297	(36,561,188)	773,712,109
In patient revenue	<u>443,464,076</u>	-	-	-	<u>443,464,076</u>	-	<u>443,464,076</u>
Total clinical revenue	<u>1,150,196,576</u>	<u>103,540,797</u>	-	-	<u>1,253,737,373</u>	<u>(36,561,188)</u>	<u>1,217,176,185</u>
Pharmacy sales	-	-	16,005,250	-	16,005,250	(847,714)	15,157,536
Others	10,995,287	5,733,127	401,903	349,215,431	366,345,748	(325,437,815)	40,907,933
Rental income	<u>821,455</u>	-	-	-	<u>821,455</u>	-	<u>821,455</u>
Total revenue	<u>1,162,013,318</u>	<u>109,273,924</u>	<u>16,407,153</u>	<u>349,215,431</u>	<u>1,636,909,826</u>	<u>(362,846,717)</u>	<u>1,274,063,109</u>
Revenue							
External customers	1,126,470,218	107,983,226	15,559,439	24,050,226	1,274,063,109	-	1,274,063,109
Inter segment	<u>35,543,100</u>	<u>1,290,698</u>	<u>847,714</u>	<u>325,165,205</u>	<u>362,846,717</u>	<u>(362,846,717)</u>	-
Total revenue	<u>1,162,013,318</u>	<u>109,273,924</u>	<u>16,407,153</u>	<u>349,215,431</u>	<u>1,636,909,826</u>	<u>(362,846,717)</u>	<u>1,274,063,109</u>
Segment profit after tax	87,129,856	(4,753,753)	675,421	(43,854,383)	39,197,141	-	39,197,141
Income tax	<u>10,302,608</u>	<u>194</u>	<u>73,599</u>	<u>(5,010,760)</u>	<u>5,365,641</u>	-	<u>5,365,641</u>
Segment profit before tax	97,432,464	(4,753,559)	749,020	(48,865,143)	44,562,782	-	44,562,782
Finance costs	<u>33,088,492</u>	<u>799,122</u>	-	<u>7,023,964</u>	<u>40,911,578</u>	-	<u>40,911,578</u>
Profit before interest, taxation (EBIT)	130,520,956	(3,954,437)	749,020	(41,841,179)	85,474,360	-	85,474,360
Depreciation	54,063,617	4,567,039	177,259	410,625	59,218,540	-	59,218,540
Amortisation	985,954	95,456	-	137,811	1,219,221	-	1,219,221
Depreciation of right-of-use asset	29,731,144	4,937,156	-	285,534	34,953,834	-	34,953,834
Profit before interest, taxation depreciation, amortisation (EBITDA)	<u>215,301,671</u>	<u>5,645,214</u>	<u>926,279</u>	<u>(41,007,209)</u>	<u>180,865,955</u>	-	<u>180,865,955</u>
Total assets as at 31 March 2025	<u>8,938,633,091</u>	<u>687,732,014</u>	<u>208,153,836</u>	<u>3,081,516,881</u>	<u>12,916,035,822</u>	<u>(6,697,122,927)</u>	<u>6,218,912,895</u>
Total liabilities as at 31 March 2025	<u>7,535,493,610</u>	<u>713,652,943</u>	<u>201,443,856</u>	<u>2,641,334,500</u>	<u>11,091,924,909</u>	<u>(6,762,870,154)</u>	<u>4,329,054,753</u>
Other disclosures:							
Additions to property and equipment	31,978,335	8,686,617	224,832	2,504,881	43,394,665	-	43,394,665
Additions to intangibles	288,699	57,500	-	-	346,199	-	346,199
Additions to capital work in progress	25,711,413	7,360,889	-	18,274,018	51,346,320	-	51,346,320

Burjeel Holdings PLC

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

31 March 2025 (Unaudited)

11 SEGMENTAL REPORTING continued

	Hospitals AED	Medical centre AED	Pharmacies AED	Others AED	Total segments AED	Adjustments and eliminations AED	Consolidation AED
31 March 2024							
<i>Revenue</i>							
Out patient revenue	698,379,628	91,994,397	-	-	790,374,025	(38,054,453)	752,319,572
In patient revenue	412,257,774	-	-	-	412,257,774	-	412,257,774
Total clinical revenue	1,110,637,402	91,994,397	-	-	1,202,631,799	(38,054,453)	1,164,577,346
Pharmacy sales	-	-	15,770,825	-	15,770,825	(47,596)	15,723,229
Others	13,873,663	1,571,005	147,087	301,360,624	316,952,379	(293,257,504)	23,694,875
Rental income	987,144	-	-	-	987,144	-	987,144
Total revenue	1,125,498,209	93,565,402	15,917,912	301,360,624	1,536,342,147	(331,359,553)	1,204,982,594
<i>Revenue</i>							
External customers	1,086,950,694	92,357,639	15,870,316	9,803,945	1,204,982,594	-	1,204,982,594
Intersegment	38,547,515	1,207,763	47,596	291,556,679	331,359,553	(331,359,553)	-
Total revenue	1,125,498,209	93,565,402	15,917,912	301,360,624	1,536,342,147	(331,359,553)	1,204,982,594
Segment profit after tax	137,142,409	12,745,305	1,721,195	(47,246,525)	104,362,384	-	104,362,384
Income tax	12,270,836	1,487,109	164,992	(2,983,624)	10,939,313	-	10,939,313
Segment profit before tax	149,413,245	14,232,414	1,886,187	(50,230,149)	115,301,697	-	115,301,697
Finance costs	28,991,335	668,433	-	3,214,276	32,874,044	-	32,874,044
Profit before interest, taxation (EBIT)	178,404,580	14,900,847	1,886,187	(47,015,873)	148,175,741	-	148,175,741
Depreciation	51,365,473	3,473,013	166,583	474,308	55,479,377	-	55,479,377
Amortisation	1,153,541	57,876	-	137,276	1,348,693	-	1,348,693
Depreciation of right-of-use asset	25,587,662	3,784,324	-	95,373	29,467,359	-	29,467,359
Profit before interest, taxation depreciation, amortisation (EBITDA)	256,511,256	22,216,060	2,052,770	(46,308,916)	234,471,170	-	234,471,170
Total assets as at 31 March 2024	8,362,483,462	586,037,478	149,759,230	2,737,031,793	11,835,311,963	(6,500,011,836)	5,335,300,127
Total liabilities as at 31 March 2024	7,046,607,495	574,729,462	146,844,296	2,460,231,070	10,228,442,323	(6,554,561,512)	3,673,880,811
Other disclosures:							
Additions to property and equipment	33,061,472	3,738,610	473,598	2,685	37,276,365	-	37,276,365
Additions to intangibles	318,487	60,814	-	-	379,301	-	379,301
Additions to capital work in progress	124,137	1,362,161	-	1,514,341	3,000,639	-	3,000,639

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

11 SEGMENTAL REPORTING continued

Revenue by Geographic segments:

	Emirate of Abu Dhabi AED	Emirate of Dubai & Northern Emirates AED	Sultanate of Oman AED	Kingdom of Saudi AED	Total AED
<i>For the three months period ended 31 March 2025</i>					
In patient revenue	366,145,687	65,027,740	12,290,649	-	443,464,076
Outpatient revenue	671,575,272	63,791,185	35,079,113	3,266,539	773,712,109
Pharmacy	15,157,536	-	-	-	15,157,536
Other income	<u>35,168,003</u>	<u>1,096,854</u>	<u>4,269,418</u>	<u>373,658</u>	<u>40,907,933</u>
	1,088,046,498	129,915,779	51,639,180	3,640,197	1,273,241,654
Rental income	<u>779,584</u>	<u>-</u>	<u>41,871</u>	<u>-</u>	<u>821,455</u>
Total revenue	<u>1,088,826,082</u>	<u>129,915,779</u>	<u>51,681,051</u>	<u>3,640,197</u>	<u>1,274,063,109</u>
<i>For the three months period ended 31 March 2024</i>					
In patient revenue	343,839,742	56,257,511	12,160,521	-	412,257,774
Out patient revenue	675,074,033	45,326,470	31,064,859	854,210	752,319,572
Pharmacy	15,723,229	-	-	-	15,723,229
Other income	<u>17,334,759</u>	<u>1,708,805</u>	<u>4,537,404</u>	<u>113,907</u>	<u>23,694,875</u>
	1,051,971,763	103,292,786	47,762,784	968,117	1,203,995,450
Rental income	<u>973,549</u>	<u>-</u>	<u>13,595</u>	<u>-</u>	<u>987,144</u>
Total revenue	<u>1,052,945,312</u>	<u>103,292,786</u>	<u>47,776,379</u>	<u>968,117</u>	<u>1,204,982,594</u>

12 ACQUISITIONS UNDER IFRS 3 BUSINESS COMBINATION

In 2025, the Group acquired the following entities. The acquisitions have been accounted for in the interim condensed consolidated financial statements using acquisition method, which reflects the economic substance of the transaction. The interim condensed consolidated financial statements include the results of the following entities from the date of acquisition.

Advanced Care Oncology Center L.L.C. ("ACOC")

The Group acquired 80% interest in Advanced Care Oncology Center L.L.C. for AED 92 million as consideration. Advanced Care Oncology Center L.L.C. is a limited liability company registered in the Emirate of Dubai, engaged in operating a cancer diseases clinic in Dubai. From the date of acquisition, Advanced Care Oncology Center L.L.C. contributed revenue and profit to the Group amounting to AED 18,031,734 and AED 3,473,022, respectively.

LLH Medical Centre Al Najda L.L.C. ("Najda")

The Group acquired 100% interest in LLH Medical Centre Al Najda L.L.C. for AED 3.2 million as consideration. LLH Medical Centre Al Najda L.L.C. is a limited liability company registered in the Emirate of Abu Dhabi, engaged in operating medical centre and providing professional safety and health consultancy in Abu Dhabi. From the date of acquisition, LLH Medical Centre Al Najda L.L.C. contributed revenue and loss to the Group amounting to AED 661,680 and AED 121,655, respectively.

Medeor Medical Center L.L.C. ("Medeor")

The Group acquired 100% interest in Medeor Medical Center L.L.C. for AED 2.3 million as consideration. Medeor Medical Center L.L.C. is a limited liability company registered in the Emirate of Abu Dhabi, engaged in operating medical center and management of medical facilities in Abu Dhabi. From the date of acquisition, Medeor Medical Center L.L.C. contributed revenue and loss to the Group amounting to AED 311,982 and AED 605,416, respectively.

12 ACQUISITIONS UNDER IFRS 3 BUSINESS COMBINATION continued

LLH Medical Centre Al Ain L.L.C. – (Al Hilal) (“Hilal”)

The Group acquired 100% interest in LLH Medical Centre Al Ain LLC - (Al Hilal) for AED 1.25 million as consideration. LLH Medical Centre Al Ain LLC - (Al Hilal) is a limited liability company registered in the Emirate of Abu Dhabi, engaged in operating medical centre in Al Ain. From the date of acquisition, LLH Medical Centre Al Ain LLC - (Al Hilal) contributed revenue and loss to the Group amounting to AED 282,830 and AED 91,343, respectively.

LLH Medical Centre Al Dhafra L.L.C. – (Hala) (“Hala”)

The Group acquired 100% interest in LLH Medical Centre Al Dhafra L.L.C. – (Hala) for AED 1.15 million as consideration. LLH Medical Centre Al Dhafra L.L.C. – (Hala) is a limited liability company, engaged in operating medical centre in Al Dhafra Region. From the date of acquisition, LLH Medical Centre Al Dhafra L.L.C. – (Hala) contributed revenue and loss to the Group amounting to AED 311,083 and AED 88,308, respectively.

Al Mokhtas Center for Physical Therapy (“Mecca Center”)

The Group acquired 100% interest in Al Mokhtas Center for Physical Therapy for AED 6.5 million as consideration. Al Mokhtas Center for Physical Therapy is a limited liability company registered in the Saudi Arabia, engaged in operating physical therapy centers in Makkah. From the date of acquisition, Al Mokhtas Center for Physical Therapy contributed revenue and loss to the Group amounting to AED 700,171 and AED 66,122, respectively.

Burjeel Holdings PLC

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 31 March 2025 (Unaudited)

12 ACQUISITIONS UNDER IFRS 3 BUSINESS COMBINATION continued

The amounts recognised in respect of the identifiable assets acquired and liabilities assumed are as set out in the table below:

	<i>ACOC AED</i>	<i>Najda AED</i>	<i>Medeor AED</i>	<i>Hilal AED</i>	<i>Hala AED</i>	<i>Mecca Center AED</i>	<i>Total AED</i>
Assets							
Property and equipment	24,550,708	88,827	164,095	227,747	23,946	1,630,729	26,686,052
Right-of-use assets	12,671,018	-	-	-	-	-	12,671,018
Inventories	1,513,793	36,536	-	-	-	-	1,550,329
Accounts receivable and prepayments	18,190,382	962,540	60,615	32,890	98,317	277,009	19,621,753
Amounts due from related parties	-	-	-	-	-	29,412	29,412
Cash and bank balance	<u>2,699,809</u>	<u>26,723</u>	<u>6,353</u>	<u>34,390</u>	<u>79,075</u>	<u>1,356</u>	<u>2,847,706</u>
	<u>59,625,710</u>	<u>1,114,626</u>	<u>231,063</u>	<u>295,027</u>	<u>201,338</u>	<u>1,938,506</u>	<u>63,406,270</u>
Liabilities							
Interest bearing loans (note 9)	2,194,429	-	-	-	-	-	2,194,429
Lease liabilities	14,354,499	-	-	-	-	-	14,354,499
Employees' end of service benefits	1,650,038	67,182	34,741	67,630	12,950	99,792	1,932,333
Account payable and accruals	15,625,503	890,541	175,951	205,940	56,849	37,949	16,992,733
Amounts due to related parties	-	97,449	-	-	-	-	97,449
	<u>33,824,469</u>	<u>1,055,172</u>	<u>210,692</u>	<u>273,570</u>	<u>69,799</u>	<u>137,741</u>	<u>35,571,443</u>
Net assets	25,801,241	59,454	20,371	21,457	131,539	1,800,765	27,834,827
Less: non-controlling interest	<u>(1,935,245)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(1,935,245)</u>
Total identifiable net assets	<u>23,865,996</u>	<u>59,454</u>	<u>20,371</u>	<u>21,457</u>	<u>131,539</u>	<u>1,800,765</u>	<u>25,899,582</u>
Consideration paid	<u>92,000,000</u>	<u>3,200,000</u>	<u>2,300,000</u>	<u>1,250,000</u>	<u>1,150,000</u>	<u>6,510,568</u>	<u>106,410,568</u>
Goodwill (provisional)	<u>68,134,004</u>	<u>3,140,546</u>	<u>2,279,629</u>	<u>1,228,543</u>	<u>1,018,461</u>	<u>4,709,803</u>	<u>80,510,986</u>
Analysis of cash flows on acquisition:							
Net cash acquired with the subsidiaries	2,699,809	26,723	6,353	34,390	79,075	1,356	2,847,706
Cash paid	<u>(92,000,000)</u>	<u>(3,200,000)</u>	<u>(2,300,000)</u>	<u>(1,250,000)</u>	<u>(1,150,000)</u>	<u>(6,510,568)</u>	<u>(106,410,568)</u>
Net cash flow on acquisition	<u>(89,300,191)</u>	<u>(3,173,277)</u>	<u>(2,293,647)</u>	<u>(1,215,610)</u>	<u>(1,070,925)</u>	<u>(6,509,212)</u>	<u>(103,562,862)</u>

The net assets recognized, are based on a provisional assessment of their fair values at the acquisition date. The Group will finalize the purchase price allocation exercise of the acquisitions before the end of the year.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

13 CONTINGENCIES AND COMMITMENTS

Contingencies

At 31 March 2025, the Group had contingent liabilities in respect of labour guarantees amounting to AED 3,956,828 (31 December 2024: AED 3,956,828) and performance guarantees amounting to AED 26,646,981 (31 December 2024: AED 26,585,123) arising in the ordinary course of business from which it is anticipated that no material liabilities will arise.

The Group is involved in various legal proceedings and claims arising in the ordinary course of business. While the outcome of these matters cannot be predicted with certainty, management does not believe that these matters will have a material adverse effect on the Group's interim condensed consolidated financial statements if concluded unfavorably.

Capital commitments

Capital expenditure contracted but not yet incurred at the end of the period / year as follows:

	31 March 2025 AED (Unaudited)	31 December 2024 AED (Audited)
Software	37,405,247	39,778,068
Building improvements	16,654,793	25,602,042
Medical equipment	18,685,817	14,119,225
Others	<u>9,680,215</u>	<u>9,670,745</u>
	<u>82,426,072</u>	<u>89,170,080</u>

14 SEASONALITY OF RESULTS

No significant income of seasonal nature was recorded in the interim condensed consolidated statement of comprehensive income for the three months period ended 31 March 2025 and 31 March 2024.

15 INCOME TAX

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major component of income tax expense in the interim condensed consolidated statement of comprehensive income are:

15.1 Amount recognised in the interim condensed consolidated statement of comprehensive income

The major components of income tax expense for the period ended are as follows:

	Three months period ended	
	(Unaudited) 31 March 2025 AED	(Unaudited) 31 March 2024 AED
Current income tax charge	5,631,687	11,259,581
Deferred income tax credit relating to origination and reversal of temporary differences	<u>(266,046)</u>	<u>(320,268)</u>
Income tax expense reported in the interim condensed consolidated statement of comprehensive income	<u>5,365,641</u>	<u>10,939,313</u>

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

15 INCOME TAX continued

15.2 Reconciliation of accounting income

	<i>Three months period ended</i>	
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>31 March</i>	<i>31 March</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
Profit before tax	44,562,782	115,301,697
Add: Profit related to foreign entities	<u>13,998,893</u>	<u>3,008,049</u>
Accounting profit before tax relating to UAE entities	<u>58,561,675</u>	<u>118,309,746</u>
At United Arab Emirates statutory income tax rate of 9%	5,270,551	10,647,877
Less: tax effect of standard exemption	(72,674)	(55,900)
Less: income not subject to tax	-	(1,188,369)
Add: tax on non-deductible expenses	167,764	944,061
Less: movement of carryforward loss	-	(27,848)
Add: tax related to foreign entities	<u>-</u>	<u>619,492</u>
Income tax expense reported consolidated statement of comprehensive income	<u>5,365,641</u>	<u>10,939,313</u>
Effective tax rate	<u>9%</u>	<u>9%</u>

At 31 March 2025 and 31 March 2024, there were no amounts recognised directly to equity or in other comprehensive income.

Income tax payable

The movement in the current taxation account is as follows:

	<i>(Unaudited)</i>	<i>(Audited)</i>
	<i>31 March</i>	<i>31 December</i>
	<i>2025</i>	<i>2024</i>
At 1 January	38,064,648	-
Charge for the period / year	5,631,687	38,064,648
Payment made during the year	<u>-</u>	<u>-</u>
	<u>43,696,335</u>	<u>38,064,648</u>

At 31 March 2025, there were no amounts recognised directly to equity or in other comprehensive income.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
31 March 2025 (Unaudited)

16 BASIC EARNINGS PER SHARE

Basic earnings per share amounts are calculated by dividing profit for the period attributable to the Equity holders of Parent by the weighted average number of ordinary shares outstanding during the period.

Diluted earnings per share amounts are calculated by dividing the profit attributable to the Equity holders of the Parent by the weighted average number of ordinary shares outstanding during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

The information necessary to calculate basic and diluted earnings per share is as follows:

	<i>Three months period ended</i>	
	<i>(Unaudited)</i>	<i>(Unaudited)</i>
	<i>31 March</i>	<i>31 March</i>
	<i>2025</i>	<i>2024</i>
	<i>AED</i>	<i>AED</i>
Earnings:		
Profit attributable to equity holders of the Parent (AED)	<u>36,379,277</u>	<u>102,018,831</u>
Number of shares		
Weighted -average number of ordinary shares for basic and diluted earnings per share	<u>5,205,134,170</u>	<u>5,205,134,170</u>
Earnings per share		
Basic and diluted earnings per share (AED)	<u>0.007</u>	<u>0.020</u>

During the period, there is no dilution in the weighted average number of shares.

There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of authorisation of these interim condensed consolidated financial statements.

17 EVENT AFTER THE REPORTING PERIOD

On 14 April 2025, the shareholders of the Company approved distribution of cash dividend at the annual general meeting of the Company amounting to AED 170 million which equals to AED 0.03 per share (three months ended 31 March 2024: AED 0.01 per share). The dividends are not recognized as a liability as at 31 March 2025.